Bludigo (Indigotindisulfonate Sodium) Patent Expiration, LOE Window & CMS Spending

Bludigo (Indigotindisulfonate Sodium) by Provepharm Sas: FDA Orange Book core substance LOE 2037-12-23, 0 AB generics, $27K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorProvepharm Sas
FDA Application & PathwayN216264 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2037-12-23
Last Listed Patent or Exclusivity Date2037-12-23
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$27K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$27K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel